Lipid peroxidation in aging brain and Alzheimer's disease

Free Radical Biology and Medicine

Volumn 33, Issue 5, 2002, Pages 620-626

  Montine, Thomas J ^a,e   Neely, M Diana ^a   Quinn, Joseph F ^b   Beal, M Flint ^c   Markesbery, William R ^d   Roberts II, L Jackson ^a   Morrow, Jason D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aging; Alzheimer's disease; Brain; Free radicals; Isoprostanes; Lipid peroxidation; Neuroprostanes

Indexed keywords

4 HYDROXYNONENAL; ACROLEIN; ALKANE DERIVATIVE; FATTY ACID DERIVATIVE; FREE RADICAL; ISOPROSTANE DERIVATIVE;

AGING; ALZHEIMER DISEASE; BLOOD LEVEL; BRAIN LEVEL; CEREBROSPINAL FLUID; CYCLIZATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; NEUROTOXICITY; OXIDATIVE STRESS; OXYGENATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW;

EID: 0036710931     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(02)00807-9     Document Type: Article

References (49)

1. Farber J.L. Mechanisms of cell injury. Craighead J.E., Pathology of environmental and occupational disease. 1995;287-302 Mosby-Year Book Inc, St. Louis, MO.
2. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128.
3. Schneider C., Tallman K.A., Porter N.A., Brash A.R. Two distinct pathways of formation of 4-hydroxynonenal mechanisms of non-enzymatic transformation of the 9- and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals . J. Biol. Chem. 276:2001;20831-20838.
4. Porter N.A., Caldwell S.E., Mills K.A. Mechanisms of free radical oxidation of unsaturated lipids. Lipids. 30:1995;277-290.
5. Mattson M.P. Modification of ion homeostasis by lipid peroxidation roles in neuronal degeneration and adaptive plasticity . Trends Neurosci. 20:1998;53-57.
6. Keller J.N., Mattson M.P. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev. Neurosci. 9:1998;105-116.
7. Smith M., Sayre L., Monnier V., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18:1995;172-176.
8. Neely M.D., Sidell K.R., Graham D.G., Montine T.J. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth and disrupts neuronal microtubules. J. Neurochem. 72:1999;2323-2333.
9. Neely M.D., Zimmerman L., Picklo M.J., Ou J.J., Morales C.R., Montine K.S., Amarnath V., Montine T.J. Congeners of Nα-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radic. Biol. Med. 29:2000;1028-1036.
10. Picklo M.J., Montine T.J. Acrolein inhibits respiration in isolated brain mitochondria. Biochim. Biophys. Acta. 1535:2001;145-152.
11. Lovell M.A., Xie C., Markesbery W.R. Acrolein, a product of lipid peroxidation, inhibits glucose and glutatmate uptake in primary neuronal cultures. Free Radic. Biol. Med. 28:2000;714-720.
12. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging. 22:2001;187-194.
13. Picklo M.J., Olson S.J., Markesbery W.R., Montine T.J. Expression and activities of aldo-keto oxidoreductases in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 60:2001;686-695.
14. McIntyre T.M., Zimmerman G.A., Prescott S.M. Biologically active oxidized phospholipids. J. Biol. Chem. 274:1999;25189-25192.
15. Morrow J., Hill K., Burk R., Nammour T., Badr K., Roberts L. A series of prostaglandin-like compounds produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87:1990;9383-9387.
16. Roberts L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., Detbarn W.D., Morrow J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273:1998;13605-13612.
17. Salem N., Kim H.Y., Yergey J.A. Docosahexaenoic acid membrane function and metabolism . Simopoulos A.P., Kifer R.R., Martin R.E., Health effects of polyunsaturated acids in seafoods. 1986;263-317 Academic Press, New York.
18. 4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry. 39:2000;2376-2383.
19. 2-isoprostanes in vitro and in vivo - effects of oxygen tension and glutathione. Arch. Biochem. Biophys. 353:1998;160-171.
20. 2-isoprostanes are increased in Alzheimer's disease. Ann. Neurol. 44:1998;410-413.
21. 2-isoprostane concentration in probable Alzheimer's disease. Neurology. 52:1999;562-565.
22. Morrow J.D., Roberts L.J. The isoprostanes unique bioactive products of lipid peroxidation . Prog. Lipid. Res. 36:1997;1-21.
23. 2α) in immature pig periventricular brain microvessels. Stroke. 31:2000;516-525.
24. Hoffman S.W., Moore S., Ellis E.F. Isoprostanes free radical-generated prostaglandins with constrictor effects on cerebral arterioles . Stroke. 28:1997;844-849.
25. Lovell M., Ehmann W., Butler S., Markesbery W. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
26. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging. 19:1998;33-36.
27. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein a novel marker of oxidative stress in Alzheimer's disease . J. Neurochem. 72:1999;751-756.
28. Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer disease. J. Neurochem. 68:1997;2092-2097.
29. Smith M.A., Sayre L.M., Anderson V.E., Harris P.L., Beal M.F., Kowall N., Perry G. Cytochemical demonstration of oxidative damage in Alzheimer's disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J. Histochem. Cytochem. 46:1998;731-735.
30. Montine K.S., Olson S.J., Amarnath V., Whetsell W.O., Graham D.G., Montine T.J. Immunochemical detection of 4-hydroxynonenal adducts in Alzheimer's disease is associated with APOE4. Am. J. Pathol. 150:1997;437-443.
31. Montine K.S., Kim P.J., Olson S.J., Markesbery W.R., Montine T.J. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropathol. Exp. Neurol. 56:1997;866-871.
32. Montine K., Reich E., Olson S.J., Markesbery W.R., Montine T. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer's disease is associated with APOE genotype. J. Neuropathol. Exp. Neurol. 57:1998;415-425.
33. Ando Y., Brannstrom T., Uchida K., Nyhlin N., Nasman B., Suhr O., Yamashita T., Olsson T., Salhy M., Uchino M., Ando M. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156:1998;172-176.
34. Smith M.A., Keisuke H., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Massimo T., Perry G. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:1998;2212-2215.
35. Lovell M.A., Xie C., Markesbery W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology. 51:1998;1562-1566.
36. Moore K., Roberts L.J. Measurement of lipid peroxidation. Free Radic. Res. 28:1998;659-671.
37. Gutteridge J.M.C., Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem. Sci. 15:1990;129-135.
38. Reich E., Markesbery W., Roberts L. II, Swift L., Morrow J., Montine T. Brain regional quantification of F-ring and D/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am. J. Pathol. 158:2001;293-297.
39. 2-isoprostanes in Alzheimer's disease evidence for enhanced lipid peroxidation in vivo . FASEB J. 12:1998;1777-1784.
40. 4-isoprostanes as specific marker of docosahexaenoic acid production in Alzheimer's disease. J. Neurochem. 72:1999;734-740.
41. Lovell M., Ehmann W., Mattson M., Markesbery W. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging. 18:1997;457-471.
42. Montine T.J., Markesbery W.R., Zackert W., Sanchez S.C., Roberts L.J., Morrow J.D. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles, or with APOE genotype in Alzheimer's disease patients. Am. J. Pathol. 155:1999;863-868.
43. 2-isoprostane concentrations in patients with Alzheimer's disease, other dementias, and age-matched controls. Arch. Pathol. Lab. Med. 125:2001;510-512.
44. 2α-IV in Alzheimer's disease correlation of a noninvasive index of lipid peroxidation with disease severity . Ann. Neurol. 48:2000;809-812.
45. Beckmam K.B., Ames B.N. The free radical theory of aging matures. Physiol. Rev. 78:1998;547-581.
46. 2-isoprostanes among patients with Huntington's disease or Alzheimer's disease, and controls. Ann. Neurol. 48:2000;950.
47. 2-isoprostanes) in smokers. N. Engl. J. Med. 332:1995;1198-1203.
48. 2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic. Biol. Med. 27:1999;463-469.
49. 2-isoprostane levels are increased in Alzheimer's disease evidence of increased oxidative stress in vivo. Alzheimer's Rep. 2:1999;277-282.